Trial · NCT03614728
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) | Part 1: GSK3326595 400 mg | 15 | 95% Confidence Interval 1.9 to 45.4 | Percentage of Participants | |
| Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) | Part 1: GSK3326595 300 mg | 18 | 95% Confidence Interval 3.8 to 43.4 | Percentage of Participants | |
| Part 1: Number of Participants With Common Non-STEAEs and STEAEs | Part 1: GSK3326595 400 mg | Common non-STEAEs | 12 | Participants | |
| Part 1: Number of Participants With Common Non-STEAEs and STEAEs | Part 1: GSK3326595 300 mg | Common non-STEAEs | 17 | Participants | |
| Part 1: Number of Participants With Common Non-STEAEs and STEAEs | Part 1: GSK3326595 400 mg | STEAEs | 11 | Participants | |
| Part 1: Number of Participants With Common Non-STEAEs and STEAEs | Part 1: GSK3326595 300 mg | STEAEs | 12 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 400 mg | Grade 1 | 0 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 300 mg | Grade 1 | 0 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 400 mg | Grade 2 | 1 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 300 mg | Grade 2 | 0 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 400 mg | Grade 3 | 0 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 300 mg | Grade 3 | 6 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 400 mg | Grade 4 | 5 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 300 mg | Grade 4 | 6 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 400 mg | Grade 5 | 7 | Participants | |
| Part 1: Number of Participants With AEs by Severity | Part 1: GSK3326595 300 mg | Grade 5 | 5 | Participants | |
| Part 1: Number of Participants With DLTs | Part 1: GSK3326595 400 mg | 0 | Participants | ||
| Part 1: Number of Participants With DLTs | Part 1: GSK3326595 300 mg | 0 | Participants | ||
| Part 1: Overall Response Rate | Part 1: GSK3326595 400 mg | 0 | 95% Confidence Interval 0.0 to 24.7 | Percentage of Participants | |
| Part 1: Overall Response Rate | Part 1: GSK3326595 300 mg | 6 | 95% Confidence Interval 0.1 to 28.7 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03614728/results